Abstract
In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guérin (BCG)-induced local immunological reaction and associated antitumor efficacy. The aim of this study was to investigate such a role for the neutrophil-attracting cytokine interleukin-8 (IL-8). The appearance of IL-8 in patients' urine after BCG therapy was compared with BCG-induced IL-6 and IL-2 and the stability of IL-8 in urine was tested. Compared to IL-6 and IL-2, a rapid induction of IL-8 was observed, occurring after the first BCG instillation. Urinary IL-8 was highly stable, even after 24 h incubation at 37°C. The IL-8 concentration after the first instillation seemed to be associated with subsequent development of an immune response. Consequently, IL-8 seems an attractive candidate for investigation of its prognostic value for a clinical response to BCG therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Agace WW, Hedges SR, Ceska M, Svanborg C (1993) Interleukin-8 and the neutrophil response to mucosal gram-negative infection. J Clin Invest 92:780
Baggiolini M, Walz A, Kunkel SL (1989) Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84:1045
Bettex-Galland M, Studer UE, Walz A, Dewald B, Baggiolini M (1991) Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration. Eur Urol 19:171
Cassatella MA (1995) The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21
De Boer EC, De Jong WH, Van Der Meijden APM, Steerenberg PA, Witjes F, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer: A flow cytofluorometric analysis. Urol Res 1:45
De Boer EC, De Reijke TM, Schamhart DHJ, Vos PCN, Kurth K-H (1993) Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. Urol Res 21:423
De Boer EC, Schamhart DHJ, Somogyi L, Kurth K-H (1995) IL-8 and onset of BCG-induced immune response. Urol Res 23:250 (P22)
De Reijke ThM. Vos PCN, De Boer EC, Bevers RFM, De Muinck Keizer WH, Kurth K-H, Schamhart DHJ (1993) Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guérin (BCG). Urol Res 21:349
De Reijke ThM, De Boer EC, Kurth K-H, Schamhart DHJ (1996) Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477
Hedges S, Svensson M, Svanborg C (1992) Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro. Infect Immun 60:1295
Jackson AM, James K (1994) Understanding the most successful immunotherapy for cancer. The Immunologist 2:208
Ratliff TL (1989) Mechanisms of action of intravesical BCG for bladder cancer. Progr Clin Biol Res 310:107
Thalmann G, Dewald B, Baggiolini M, Studer U (1993) Kinetics and stability of interleukin-8 (IL-8) in the urine after transurethral resection (TUR-B) and after intravesical instillations with bacillus Calmette-Guérin (BCG) in patients with superficial bladder cancer. J Urol 149:337A
Van Der Sloot E, Kuster S, Böhle A, Braun J, Wood WG (1992) Towards an understanding of the mode of action of bacillus Calmette-Guérin therapy in bladder cancer treatment, especially with regard to the role of fibronectin. Eur J Clin Chem Clin Biochem 30:503
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Boer, E.C., Somogyi, L., de Ruiter, G.J.W. et al. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol. Res. 25, 31–34 (1997). https://doi.org/10.1007/BF00941903
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00941903